Oppenheimer raised Intec Pharma (NTEC) price target to $15 from $10, reiterating its outperform rating.

According to the broker the company’s share outperformance since June was driven by a number of recent events that have resonated well with investors. They also emphasized clinical and operational progress that is being made under the leadership of new management, in addition to what they see as an increasingly favorable regulatory and deal-making environment, especially for companies involved in neuroscience.

The broker said it is optimistic about the prospects for the company’s clinical assets which rely on the Accordion Pill (AP) platform: 1) AP-CD/LD for Parkinson’s disease (PD) and 2) AP-CBD/THC for chronic pain. “We believe AP
provides a simple yet elegant solution to important unmet needs in neuroscience,” said Oppenheimer.


Fatal error: Call to undefined function printFooterForm() in /home4/mando123/public_html/collinscourier.com/wp-content/themes/alpha/single.php on line 57